Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, PO Box 285, Hills Road, Cambridge CB2 0QQ, UK.
Diabetologia. 2013 Sep;56(9):1907-13. doi: 10.1007/s00125-013-2945-6. Epub 2013 May 24.
AIMS/HYPOTHESIS: The association between the mitochondrial DNA 16181-16193 polycytosine variant (known as the OriB variant as it maps to the OriB origin of replication) and type 2 diabetes has not been reliably characterised, with studies reporting conflicting results. We report a systematic review of published literature in Europid populations, new data from the Norfolk Diabetes Case-Control Study and a meta-analysis to help quantify this association.
We performed a systematic review identifying all the studies of the OriB variant and type 2 diabetes in Europid populations published before January 2013. We typed the OriB variant by pyrosequencing and sequencing in the Norfolk Diabetes Case-Control Study, which comprised 5,574 type 2 diabetes cases and 6,950 population-based controls.
Overall, the meta-analysis included eight published studies plus the current new results, with a total of 11,794 type 2 diabetes cases and 14,465 controls. In the Norfolk Diabetes Case-Control Study, the OR for type 2 diabetes for the OriB variant was 1.09 (95% CI 0.96, 1.24). In a combined analysis, the relative risk for type 2 diabetes for the OriB variant in Europid populations was 1.10 (95% CI 1.01, 1.20; p = 0.03) CONCLUSIONS/INTERPRETATION: Results from this systematic review and meta-analysis suggest that the mitochondrial DNA OriB variant is modestly associated with an increased risk of type 2 diabetes in Europid populations, with an effect size comparable with that of recently identified variants from genome-wide association studies.
目的/假设:线粒体 DNA 16181-16193 多聚胞嘧啶变异(因其位于复制起点 OriB 而被称为 OriB 变异)与 2 型糖尿病之间的关联尚未得到可靠描述,研究结果相互矛盾。我们报告了对欧洲人群发表文献的系统评价,来自诺福克糖尿病病例对照研究的新数据以及荟萃分析,以帮助量化这种关联。
我们进行了系统评价,确定了在 2013 年 1 月之前发表的所有关于 OriB 变异与 2 型糖尿病的欧洲人群研究。我们通过焦磷酸测序和测序对诺福克糖尿病病例对照研究中的 OriB 变异进行了基因分型,该研究包括 5574 例 2 型糖尿病病例和 6950 例基于人群的对照。
总体而言,荟萃分析包括八项已发表的研究以及当前的新结果,共有 11794 例 2 型糖尿病病例和 14465 例对照。在诺福克糖尿病病例对照研究中,OriB 变异与 2 型糖尿病的 OR 为 1.09(95%CI 0.96, 1.24)。在合并分析中,OriB 变异在欧洲人群中发生 2 型糖尿病的相对风险为 1.10(95%CI 1.01, 1.20;p=0.03)。
结论/解释:这项系统评价和荟萃分析的结果表明,线粒体 DNA OriB 变异与欧洲人群 2 型糖尿病的风险增加适度相关,其作用大小与全基因组关联研究中最近发现的变异相当。